Search
 
 
Edit Shopping CART(106)  |  Sunday, November 22, 2009
 
 
ARTICLES  &  COMMENTARY
Medicare Coverage Policies for Biologics: The Broad Gray Line
 
Shuffle - Joseph Antos
  
 

Wilson H. Taylor Scholar
Joseph Antos


 
In October 2007, American Health & Drug Benefits asked Dr. Joseph Antos to discuss the forces that have shaped Medicare's policies and their impact on the various stakeholders in US healthcare. The first part of the interview appeared in AHDB

in February 2008. This second part focuses on the impact of the Centers for Medicare & Medicaid Services drug coverage on the future of biologic products. This discussion does not reflect any new developments occurring after October, such as the recent recommendation of the US Food and Drug Administration advisory committee to narrow the indication for erythropoiesis-stimulating agents to patients with cancer.

 

  Click here to view the entire interview as an Adobe Acrobat PDF.

 

 

Joseph Antos is the Wilson H. Taylor Scholar in Health Care and Retirement Policy at AEI. Robert Henry is the editor-in-chief for American Health & Drug Benefits